GET DAILY SIGNALSPDS Biotechnology (PDSB) Shares Rise +70% on Clinical Pipeline Updates
Key Takeaways
- PDSB shares rose roughly 70% over the last 30 days, climbing from about $0.77 to around $1.30.
- The rally accelerated after the company's October 6 key opinion leader (KOL) event spotlighting its PDS0301 program in advanced colorectal cancer.
- Publication of VERSATILE-002 Phase 2 results in JAMA Oncology reinforced the clinical narrative around lead candidate PDS0101.
- The quarterly trend is also strongly positive, with the stock up approximately 88% over the past three months.
- Pipeline prioritization and financing decisions, including a workforce reduction and a Nant-led financing, remain central investor considerations.
- For additional detail on analyst views and projections, explore the company's Price Targets, Earnings, and Forecast pages.
Company Overview and Market Position
PDS Biotechnology Corporation is a late-stage immuno-oncology company based in Princeton, New Jersey, focused on developing targeted cancer immunotherapies. Its proprietary Versamune platform is designed to train the immune system to recognize and attack cancers by promoting the activation of disease-specific T cells.
The company's lead candidate is PDS0101, an HPV16-targeted immunotherapy evaluated in combination with checkpoint inhibitors for HPV16-positive head and neck cancers and other HPV-associated malignancies. PDS Biotechnology is also prioritizing PDS0301, a Versamune-based candidate being developed for metastatic colorectal cancer. I reviewed some of the comparative data points using Tickeron’s AI Screener to see how the stock fits within the broader biotech space. Investors follow the stock closely because the company is advancing late-stage clinical programs with substantial addressable markets, while remaining a clinical-stage business that is not yet generating product revenue.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PDSB has moved from a closing price of roughly $0.77 to around $1.30, a gain of approximately 70%. The advance was punctuated by a sharp surge in early October, when trading volume spiked to more than 60 million shares in a single session as investors reacted to news around the PDS0301 program. The stock subsequently climbed to an intraday peak near $1.79 before pulling back and consolidating in the low-$1 range.
The broader quarterly trend has been even more pronounced. Compared with its closing level of about $0.69 three months earlier, the stock has advanced roughly 88%, reflecting sustained positive momentum as the company reshaped its pipeline focus and highlighted new clinical data.
What Drove the Recent 30-Day Move
The primary catalyst behind the recent move was the company's October 6 KOL event on PDS0301 for the treatment of advanced colorectal cancer with liver metastases. Management described more durable responses in heavily pretreated patients and indicated it is preparing a Phase 3 trial, with a targeted start around the first quarter of 2027. This clearer path toward a registrational study reframed investor expectations for the company's most advanced program.
Additional developments reinforced the move. In mid-September, results from the VERSATILE-002 Phase 2 trial of PDS0101 in combination with pembrolizumab were published in JAMA Oncology, reporting a median overall survival of 39.3 months in first-line, recurrent or metastatic, immune checkpoint inhibitor-naive patients. The company also announced board appointments bringing added corporate development and regulatory experience.
At the same time, capital-structure news remained in focus. In mid-October, a registration statement was filed for the potential resale of up to 16.5 million shares by selling stockholders, although the company itself was not selling shares. These factors, combined with elevated retail and institutional trading volume, contributed to the stock's volatility over the period.
Drivers Behind the Quarterly Performance
The three-month advance reflects a broader strategic realignment rather than a single event. In August, the company approved a reduction in force affecting roughly 36% of its workforce as it narrowed its focus toward PDS0301 while preserving PDS0101 through partnerships. A Nant-led financing was widely viewed as a positive step in supporting that prioritization, though analysts have continued to flag funding risk given the company's limited cash position and the contingent structure of part of the financing.
Analyst commentary over the quarter reflected this tension between optimism about the refocused pipeline and caution on execution and capital needs. Price-target revisions trended lower alongside the sharper focus, yet the market's reaction to the company's clinical updates ultimately drove shares higher through the period.
What to Watch Next
Looking ahead, the most important catalysts include the company's next earnings report, estimated for November 12, 2026, where updates on cash runway and clinical timelines will be closely scrutinized. Progress toward the planned Phase 3 initiation for PDS0301 in metastatic colorectal cancer is a central watch item, as is any additional data readout from the program.
Investors should also monitor financing developments, analyst rating changes, and broader biotechnology-sector sentiment. As a clinical-stage company, PDSB carries meaningful execution and dilution risk, and its valuation can swing sharply on clinical, regulatory, and capital-markets news. None of these observations constitute investment advice, and outcomes remain inherently uncertain.
AI Tools in My Research Process
One resource I turn to regularly for pattern recognition and strategy testing is Tickeron’s AI Trading Bots. These automated systems scan thousands of tickers across different timeframes and risk profiles, allowing me to cross-check ideas against data-driven models without replacing my own fundamental work. I find the curated trending section particularly useful when evaluating momentum names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PDSB in +35.30% Uptrend, growing for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Aroon Indicator entered an Uptrend today. In 82 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for PDSB moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 70 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 45 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-26.319) is normal, around the industry mean (3.037). P/E Ratio (-2.031) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
Advertisement